Sanofi (LON:0O59)
London
· Delayed Price · Currency is GBP · Price in EUR | Market Cap | 87.15B |
| Revenue (ttm) | 40.75B |
| Net Income (ttm) | 6.82B |
| Shares Out | n/a |
| EPS (ttm) | 5.56 |
| PE Ratio | 12.79 |
| Forward PE | 9.85 |
| Dividend | 3.30 (4.13%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 1,898,144 |
| Average Volume | 2,036,583 |
| Open | 81.95 |
| Previous Close | 80.83 |
| Day's Range | 78.80 - 82.75 |
| 52-Week Range | 75.76 - 110.84 |
| Beta | 0.37 |
| RSI | 57.78 |
| Earnings Date | Apr 23, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsNews
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 s...
Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study d...
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions
Texas Attorney General Ken Paxton on Thursday sued Sanofi for allegedly "bribing" providers to prescribe its medications over alternatives.
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Sanofi announces leadership evolution in Specialty Care Business Unit
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026.
Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees
French drugmaker Sanofi said on Monday it will expand its global capability centre (GCC) in the southern Indian city of Hyderabad, and increase its workforce to more than 4,500 employees.
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV...
Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
Sanofi SA (NASDAQ: SNY) shares are down during Friday's premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.
Sanofi's new CEO needs to fix drug pipeline and navigate Trump
Sanofi's incoming CEO, 65-year-old Belén Garijo, faces a major task to win over investors, accelerate the French company's stalled drug development pipeline and navigate vaccine scepticism in the Unit...
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Sanofi reported FY net sales up >9% to €43.6bn and net income up >12% to €9.5mn. Despite strong results, Sanofi announced today it has replaced CEO Paul Hudson with former employee Belén Garijo, signa...
Who is Sanofi's new CEO Belén Garijo?
French drugmaker Sanofi on Thursday appointed Belén Garijo as its new chief executive after choosing not to renew the mandate of Paul Hudson.
Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO
Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.
Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate
French drugmaker Sanofi said on Thursday it had appointed Belén Garijo as its new chief executive after deciding not to renew the mandate of current CEO Paul Hudson.
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson.
Sanofi: Information concerning the total number of voting rights and shares – January 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Press Release: Sanofi completes the acquisition of Dynavax
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax).
Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
The US and Japan granted breakthrough therapy/orphan status to rilzabrutinib for wAIHA, a rare blood disorder marked by the destruction of red blood cells
Oakmark International Strategy Q4 2025 New Investments And Divestments
Oakmark International Strategy Q4 2025 New Investments And Divestments
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer
Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, resp...
Sanofi's genetic disorder drug shows mixed results in late-stage trials
French drugmaker Sanofi said on Monday that its experimental genetic disorder treatment showed promise in a late-stage study of patients with a type of Gaucher disease, but failed to meet the main goa...
Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world ev...
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript